Recent advances in emerging PCOS therapies

Polycystic ovary syndrome is a prevalent endocrinopathy involving androgen excess, and anovulatory infertility. The disorder is also associated with many comorbidities such as obesity and hyperinsulinemia, and an increased risk of car-diovascular complications. Reproductive, endocrine, and metabolic symptoms are highly variable, with heterogenous phenotypes adding complexity to clinical management of symptoms. This review highlights recent findings regarding emerging therapies for treating polycystic ovary syndrome, including i) pharmacological agents to target androgen excess, ii) modulation of kisspeptin signalling to target central neuro-endocrine dysregulation, and iii) novel insulin sensitisers to combat peripheral metabolic dysfunction.

Automated summary

Polycystic ovary syndrome is a common endocrine disorder characterized by excessive levels of androgen and anovulatory infertility. It is also associated with comorbidities such as obesity, hyperinsulinemia, and increased risk of cardiovascular complications. The symptoms related to reproduction, endocrine, and metabolism vary greatly, posing challenges for clinical management.